近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long H, Medina-Lara A, et al (In Press). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model. Health Technology Assessment Abstract. Full text.
Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, et al (2016). Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess, 20(62), 1-594. Abstract. Author URL. Full text. Article has an altmetric score of 9
Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C (2015). A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer, 15 Abstract. Author URL. Full text. Article has an altmetric score of 8
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long L, Medina-Lara A, et al (2014). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model. Author URL.
Ciani O, Hoyle M, Pavey T, Cooper C, Garside R, Rudin C, Taylor R (2013). Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case-study for technology appraisal on the basis of surrogate outcomes evidence. Value in Health, 6(16), 1081-1090.
Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C (2013). Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. Value Health, 16(2), 288-296. Abstract. Author URL.
Peters JL, Anderson R, Hoyle M, Hyde C (2013). Evolution of a cost-utility model of donepezil for Alzheimer's disease. Int J Technol Assess Health Care, 29(2), 147-154. Abstract. Author URL.
Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P, Moxham T, et al (2013). Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. Age Ageing, 42(1), 14-20. Abstract. Author URL. Article has an altmetric score of 4
Joulain F, Proskorovsky I, Allegra C, Tabernero J, Hoyle M, Iqbal SU, Van Cutsem E (2013). Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. British Journal of Cancer, 109(7), 1735-1743. Author URL.
Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P, Hyde C (2013). The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess, 17(14), 1-237. Abstract. Author URL. Full text. Article has an altmetric score of 4
Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K (2012). Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess, 16(22), 1-410. Abstract. Author URL. Full text. Article has an altmetric score of 3
Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2012). Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: Systematic reviews and economic analyses. Health Technology Assessment, 16, 1-278. Abstract. Author URL.
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, et al (2012). The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess, 16(21), 1-470. Abstract. Author URL. Full text. Article has an altmetric score of 11
Hoyle M (2011). Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis. Pharmacoeconomics, 29(1), 1-15. Abstract. Author URL. Article has an altmetric score of 3
Hoyle M, Rogers G, Moxham T, Liu Z, Stein K (2011). Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health, 14(8), 1057-1067. Abstract. Author URL.
Hoyle MW (2011). GENERAL METHODOLOGICAL ISSUES IN COST-EFFECTIVENESS ANALYSIS INSPIRED BY THE ASSESSMENT OF DASATINIB, NILOTINIB AND IMATINIB FOR CHRONIC MYELOID LEUKAEMIA. VALUE IN HEALTH, 14(7), A425-A425. Author URL.
Hoyle MW, Henley W (2011). Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol, 11. For Spreadsheet to implement method, click on Author URL Abstract. Author URL. Full text. Article has an altmetric score of 4
Hoyle M, Crathorne L, Garside R, Hyde C (2011). Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Health Technol Assess, 15 Suppl 1, 61-67. Abstract.
京公网安备 11010802027423号